Successful emerging life sciences companies have an early understanding of compliance guidelines, including when to implement GLP, GMP, and GCP workflows, technologies and best practices. Marching too fast can be costly and slow down development; going too slow can result in additional regulatory scrutiny and delays. David Grote, Head of Quality at Immunocore outlines how to identify when to apply compliance principles in the drug development journey, and how to implement GxP guidances, workflows, helpful technologies, and best practices.